Emcure Pharmaceuticals Cuts Poviztra® Starting Dose Price by 55% to ₹3,999 Per Month
Emcure Pharmaceuticals has significantly reduced prices for its weight management drug Poviztra® (semaglutide injection) across India, with the starting dose price cut by 55% to ₹3,999 per month. The comprehensive price revision covers all five dosage strengths and aims to address India's growing obesity epidemic affecting over 254 million people with generalized obesity.
*this image is generated using AI for illustrative purposes only.
Emcure Pharmaceuticals has announced a significant price reduction for its weight management drug Poviztra® (semaglutide injection) across India, effective April 3, 2026. The pharmaceutical company has reduced the starting dose price by 55% to ₹3,999 per month, marking a substantial step toward improving patient access to essential obesity treatment.
Major Price Reduction Initiative
The company has implemented comprehensive pricing restructure for Poviztra® across all dosage strengths. As the first Indian company to exclusively distribute and commercialize Poviztra®, a second brand of Novo Nordisk's semaglutide injection for obesity, Emcure aims to expand access and enable more patients to benefit from this proven therapy.
| Dosage | Old Monthly Price (₹) | Revised Monthly Price (₹) | Reduction (%) |
|---|---|---|---|
| Poviztra® 0.25 mg | 8,790 | 3,999 | 55% |
| Poviztra® 0.5 mg | 11,200 | 4,999 | 55% |
| Poviztra® 1 mg | 11,200 | 5,999 | 46% |
| Poviztra® 1.7 mg | 13,000 | 7,999 | 38% |
| Poviztra® 2.4 mg | 15,000 | 8,999 | 40% |
Addressing India's Obesity Challenge
The price revision comes at a critical time when obesity and weight-related health conditions are emerging as one of India's most pressing public health challenges. According to recent data, nearly 254 million people are living with generalized obesity and 351 million with abdominal obesity in India.
Satish Mehta, Chief Executive Officer and Managing Director, Emcure Pharma, stated: "The revised pricing of Poviztra® is a step towards making scientifically validated weight-management therapies more accessible and affordable to a wider patient base. Improving access to a globally established molecule like semaglutide is crucial to addressing this public health challenge at scale."
Product Features and Clinical Evidence
Poviztra® is available in a once-weekly pen device in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg. The state-of-the-art pen device provides convenience of simple administration and precise dosing. The innovator biologic rDNA semaglutide molecule has been on the market for close to a decade and is backed by nearly 50 clinical trials in diverse clinical settings, with an equivalent of 49+ million patient years of exposure.
Obesity is linked to over 230 health complications including cardiovascular disease, type 2 diabetes, hypertension, fatty liver, knee osteoarthritis, polycystic ovary syndrome, kidney disease and Alzheimer's disease. With this price reduction, Emcure Pharma reinforces its commitment to advancing patient access, improving health outcomes, and supporting innovative treatments that address the growing burden of obesity in India.
Source: None/Company/INE168P01015/8f5492a5-8612-4da0-aa85-2d0e0e672304.pdf
Historical Stock Returns for Emcure Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.67% | -2.87% | +6.33% | +18.65% | +43.82% | +13.87% |
How will this aggressive pricing strategy impact Emcure's profit margins and overall financial performance in the obesity treatment segment?
Could this price reduction trigger a broader price war among other pharmaceutical companies offering weight management drugs in India?
What market share gains does Emcure expect to achieve with this 55% price cut, and how might it affect Novo Nordisk's original semaglutide sales?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
